[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"minimally-invasive-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:minimally-invasive-treatment":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100608941","stereotactic-thrombolysis-with-tenecteplase-for-supratentorial-intracerebral-hemorrhage-100608941",false,"NCT07208097","Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage","STEPS","Inclusion Criteria ：\n\n1. . Age 18 to 80 years, any gender.\n2. . Clinically confirmed acute spontaneous supratentorial intracerebral hemorrhage (ICH), with diagnostic CT completed within 24 hours of symptom onset (for patients with unknown time of onset or wake-up stroke, the time from the last known well to symptom detection is used as the presumed onset time).\n3. . CT-confirmed supratentorial ICH with hematoma volume calculated by ABC\u002F2 method between 25 mL and 60 mL (inclusive).\n4. . National Institutes of Health Stroke Scale (NIHSS) score ≥ 6.\n5. .Glasgow Coma Scale (GCS) score between 9 and 14 (inclusive).\n6. . Pre-stroke modified Rankin Scale (mRS) score ≤ 1.\n7. . Good compliance, with written informed consent provided by the patient and\u002For legal guardian, and ability to adhere to the scheduled follow-up visits.\n\nExclusion Criteria：\n\n1. . Brainstem or cerebellar hemorrhage; or thalamic hemorrhage with significant midbrain shift accompanied by third nerve palsy or unreactive dilated pupils.\n2. . Irreversible brainstem dysfunction (bilateral fixed, dilated pupils and decerebrate posturing).\n3. . Secondary ICH caused by: head trauma, arteriovenous malformation (AVM), moyamoya disease, intracranial aneurysm, coagulation disorders (hereditary or acquired hemorrhagic diathesis, hemophilia, coagulation factor deficiency, leukemia, etc.), hemorrhagic transformation of cerebral infarction, or tumor; multiple intracranial hemorrhages, subarachnoid hemorrhage (SAH), primary intraventricular hemorrhage, drug-induced hemorrhagic stroke, subdural hemorrhage, epidural hemorrhage.\n4. . Significant abnormalities in the following laboratory parameters:(1)International normalized ratio (INR) \\> 1.4; any irreversible coagulopathy or known coagulation disorder that cannot be corrected with procoagulants to maintain INR ≤ 1.4. (2) Severe hepatic insufficiency: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 3 times the upper limit of normal (ULN). (3) Severe renal insufficiency: estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin\u002F1.73m². (4)Hemoglobin \\\u003C 90 g\u002FL.5）Platelet count \\\u003C 100 × 10⁹\u002FL.\n5. . History of malignancy, autoimmune diseases (including but not limited to systemic lupus erythematosus, systemic vasculitis), hemorrhagic diathesis (including various hereditary and acquired bleeding disorders), malignant arrhythmias, cardiac insufficiency (B-type natriuretic peptide \\[BNP\\] ≥ 1000 pg\u002FmL or left ventricular ejection fraction \\[LVEF\\] ≤ 40%), acute myocardial infarction, acute or severe infectious diseases (e.g., intracranial infection, severe pneumonia, sepsis), or any other severe concurrent illness that may exacerbate the condition or interfere with efficacy assessment.\n6. . Known high risk of thromboembolism, including: presence of a mechanical heart valve prosthesis, history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis. (Note: Atrial fibrillation without mitral stenosis is permitted).\n7. . Myocardial infarction within 30 days prior to randomization.\n8. .Use of anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, apixaban) within 1 week prior to symptom onset.\n9. . History of internal bleeding (e.g., gastrointestinal bleeding, genitourinary bleeding, retroperitoneal bleeding) within 3 months prior to randomization.\n10. . Major surgery or vascular puncture (e.g., venesection, arterial puncture) within 3 months prior to randomization.\n11. . History of significant head trauma or severe stroke within 3 months prior to randomization.\n12. . History of intracerebral hemorrhage within 1 year prior to randomization.\n13. . Indications for craniotomy: (1) Progressive impairment of consciousness; (2)Preoperative signs of brain herniation (e.g., foramen magnum herniation, tentorial herniation) posing a life-threatening condition.\n14. . Intraventricular hemorrhage (IVH) or ICH with rupture into the ventricle causing intraventricular cast formation and\u002For hydrocephalus anticipated to require external ventricular drainage (EVD).\n15. . Patient or family requests craniotomy or neuroendoscopic surgery for hematoma evacuation.\n16. . Pre-randomization decision by patient\u002Ffamily for Do-Not-Resuscitate (DNR) or Do-Not-Intubate (DNI) orders regarding life-sustaining measures.\n17. . Known hypersensitivity or intolerance to TNK.\n18. . Pregnancy (positive urine pregnancy test) in women of childbearing potential.\n19. . Concurrent participation in another investigational drug or device study.\n20. . History of drug or alcohol abuse\u002Fdependence, severe dementia, or psychiatric disorder prior to randomization, anticipated to result in poor compliance and inability to complete follow-up.","ALL","18 Years","80 Years",{"count":20,"type":21},768,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is an phase III prospective, multi-center, open-label, randomized controlled trial (RCT) with blinded endpoint assessment. It plans to enroll 768 subjects with spontaneous supratentorial intracerebral hemorrhage, who will be randomly assigned in a 1:1 ratio to the investigational arm (stereotactic minimally invasive puncture for intracerebral hemorrhage combined with TNK liquefaction drainage, single TNK dose of 0.5mg per time or the standard medical treatment group.",[27,28],"Intracerebral Haemorrhage","Minimally Invasive Treatment",[30,31,32,33],"intracerebral haemorrhage","minimally invasive treatment","hematoma evacuation","tenecteplase","RECRUITING","2025-11-27",{"date":37,"type":38},"2025-12-01","ACTUAL",{"date":40,"type":38},"2025-10-25",{"date":42,"type":21},"2028-06-30",{"name":44,"class":45},"Tongji Hospital","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100554981","a-prospective-evaluation-of-microwave-ablation-mwa-in-the-treatment-of-relapsed-graves-disease-100554981","NCT06506149","A Prospective Evaluation of Microwave Ablation (MWA) in the Treatment of Relapsed Graves' Disease","Inclusion Criteria:\n\n* (a) age older than 18 years,\n* (b) relapsed Graves' disease despite an adequate ATD treatment for 18 months or more\n* (c) absence of vocal cord immobility\n\nExclusion Criteria:\n\n* (a) patients who prefer or are indicated for surgery,\n* (b) presence of head and\u002For neck disease preventing hyperextension of the neck,\n* (c) history of thyroid cancer or other malignant tumours in the neck region,\n* (d) history of neck irradiation,\n* (e) severe Graves' ophthalmopathy,\n* (f) large compressive goitre,\n* (g) pregnancy or lactation, and\n* (h) any contraindication to intravenous sedation.",{"count":53,"type":21},25,[24],"Graves' disease is the most common cause of hyperthyroidism, with conventional treatment options being anti-thyroid drugs (ATD), radioiodine (RAI) and surgery. For ATD, it has been the first-line treatment over decades. Despite its ability to induce remission, minor side effects such as skin rash, gastrointestinal disturbance and arthralgia occur in around 5% of patients, while serious adverse reactions including agranulocytosis and hepatotoxicity are potentially life threatening. Patients are usually treated with ATD for 12 to 18 months but the relapse rate was reported to be up to 50-60% which these patients would require more definitive treatment options with RAI or thyroidectomy. However, RAI is not preferable in patients with Graves' ophthalmopathy as it could further worsen eye symptoms. RAI may also cause hypothyroidism in a substantial proportion of patients, with a subsequent need for lifelong thyroxine replacement. As for thyroidectomy, it carries an overall 2-10% risk of complications including bleeding, transient or permanent recurrent laryngeal nerve injury and hypoparathyroidism. Due to the drawbacks of the various conventional treatment options, there has been increasing interest in the development of minimally invasive treatment alternatives in recent years. With the evolution of thermal ablative strategies, high-intensity focused ultrasound (HIFU) and radiofrequency ablation (RFA) have been reported as feasible treatment options for relapsed Graves' disease. There has also been increasing reports in the use of microwave ablation (MWA) in the treatment of benign thyroid nodules. MWA works via generation of electromagnetic field and is performed by inserting a microwave antenna into the thyroid gland percutaneously under ultrasound (USG) guidance. The active tip of the antenna causes oscillation of the surrounding water molecules which induces frictional heat and creates a thermal ablative effect. As compared to RFA, MWA is not affected by heat sink effect and may require a shorter treatment time. Similar to other thermal ablative approaches, MWA has the merits of avoiding surgical scar, organ preservation as well as being an ambulatory procedure.",[57,28,58],"Graves Disease","Ablation Treatment",[60,61,62,63],"Graves disease","Thyroid function","remission","non surgical","2024-07-25",{"date":66,"type":38},"2024-07-29",{"date":68,"type":38},"2023-07-04",{"date":70,"type":21},"2026-06-30",{"name":72,"class":45},"The University of Hong Kong",1]